CJC-1295 Benefits: Claims vs What Studies Show
Benefits people claim for CJC-1295, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 4 / 2
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- research chemical
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Growth hormone | Human RCT evidence, 4 of 4 | 2 / 2 | GH and IGF-I; Repeat dosing; GH secretion pattern | Evidence for growth hormone |
| Hormone balance | Human RCT evidence, 4 of 4 | 2 / 0 | GH and IGF-I; Repeat dosing; GH secretion pattern | Evidence for hormone balance |
| Muscle growth | Human observational evidence, 3 of 4 | 1 / 0 | Reasons for use reported on forums; Regulatory status and evidence for physique claims | Evidence for muscle growth |
| Weight loss | Human observational evidence, 3 of 4 | 1 / 0 | Reasons for use reported on forums | Evidence for weight loss |
| Sleep | Human observational evidence, 3 of 4 | 1 / 0 | Reasons for use reported on forums | Evidence for sleep |
| Bodybuilding | Review only | 0 / 0 | Regulatory status and evidence for physique claims | Evidence for bodybuilding |
Strongest study per claim: Growth hormone, The Journal of clinical endocrinology and metabolism 2006, PMID 16352683; Hormone balance, The Journal of clinical endocrinology and metabolism 2006, PMID 16352683; Muscle growth, Substance use & misuse 2016, PMID 26771670.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| GH and IGF-I | A single injection raised mean plasma GH 2- to 10-fold for 6 days or more and mean IGF-I 1.5- to 3-fold for 9-11 days, dose-dependently. | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| Repeat dosing | After multiple doses, mean IGF-I stayed above baseline for up to 28 days. | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| Reasons for use reported on forums | Forum users cited weight loss, muscle enhancement, youthful skin, improved sleep and injury healing as reasons for use; these are user-stated motives, not measured results. | Human observational | Substance use & misuse 2016, PMID 26771670 |
| Serum protein changes | CJC analog injection changed the intensity of five serum protein spots; these are candidate biomarkers of GH/IGF-1 action, not clinical outcomes. | Human uncontrolled trialn = 11 | Growth hormone & IGF research 2009, PMID 19386527 |
| GH secretion pattern | Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45% one week after a single injection, with GH pulsatility preserved. | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
| GH pulses | Frequency and magnitude of GH pulses were unchanged. | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2006, PMID 17018654 |
| Regulatory status and evidence for physique claims | The review notes no regulatory approval for physique- or performance-related indications of these peptides, including this long-acting GHRH analog. | Review | Frontiers in endocrinology 2026, PMID 42395176 |
| Growth and body composition | Once-daily CJC-1295 maintained normal growth and body composition in GHRH knockout mice. | Animal · mouse (not a human result) | American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960 |
| Dosing interval | The same dose was less effective given every 48 or 72 h. | Animal · mouse (not a human result) | American journal of physiology. Endocrinology and metabolism 2006, PMID 16822960 |
| GH release | CJC-1295 produced a 4-fold larger 2-h GH area under the curve than hGRF(1-29) in rats. | Animal · rat (not a human result) | Endocrinology 2005, PMID 15817669 |
What people claim, per a study of forum threads
A netnography of forum threads found that people chose CJC-1295 for weight loss, muscle enhancement, youthful skin, improved sleep and injury healing.[2]
Claim: it raises growth hormone and IGF-1
In healthy adults a single injection gave dose-dependent GH increases of 2- to 10-fold for 6 days or more, and IGF-I increases of 1.5- to 3-fold.[1]
In the pulsatility study of healthy men, IGF-I levels were 45% higher after CJC-1295.[4]
In rats, CJC-1295 gave a 4-fold increase in GH area under the curve over a 2-hour period compared with the native peptide; this is animal data.[7]
Claim: it builds muscle and burns fat
In GHRH-knockout mice, relative lean mass and subcutaneous fat mass were normal in all treated groups; this is mouse data, not muscle gain in healthy animals.[6]
A review of performance-enhancing peptides highlights uncertainty around putative performance and recomposition benefits.[5]
Claim: better sleep, younger skin, faster healing
None of the 7 abstracts cached for this page reports a sleep, skin or injury-healing outcome: they measure growth hormone, IGF-I, serum proteins, growth in knockout mice, and forum use.
Calculated from abstracts checked 16352683, 17018654, 19386527, 16822960, 15817669, 26771670, 42395176; sleep skin healing outcomes found 0. Formula: count of cached abstracts naming those outcomes
How little research sits behind weight loss
A PubMed search of CJC-1295 with weight-loss terms (2026-10-02) found 2 human-only papers and 1 under the animal filter; 0 carried a randomized-trial tag.
Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND ("weight loss"[tiab] OR "weight reduction"[tiab] OR "body weight"[tiab] OR obes*[tiab] OR overweight[tiab] OR adiposity[tiab] OR "fat mass"[tiab] OR "body fat"[tiab] OR "fat loss"[tiab]); date 2026-10-02; human only count 2; animal filter count 1; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
How little research sits behind muscle growth
A PubMed search of CJC-1295 with muscle-growth terms (2026-10-02) found 1 human-only papers and 1 under the animal filter; 0 carried a randomized-trial tag.
Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND ("muscle mass"[tiab] OR "lean mass"[tiab] OR "lean body mass"[tiab] OR "fat-free mass"[tiab] OR "muscle growth"[tiab] OR "muscle hypertrophy"[tiab] OR "muscle protein synthesis"[tiab] OR "muscle strength"[tiab] OR sarcopeni*[tiab] OR "muscle wasting"[tiab] OR "muscle atrophy"[tiab]); date 2026-10-02; human only count 1; animal filter count 1; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
How little research sits behind bodybuilding
A PubMed search of CJC-1295 with bodybuilding terms (2026-10-02) found 3 human-only papers and 1 under the animal filter; 0 carried a randomized-trial tag.
Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (bodybuild*[tiab] OR "resistance training"[tiab] OR "resistance exercise"[tiab] OR "strength training"[tiab] OR "weight training"[tiab] OR weightlift*[tiab] OR "muscle hypertrophy"[tiab] OR "muscle mass"[tiab] OR "lean mass"[tiab] OR "anabolic steroid"[tiab] OR "anabolic steroids"[tiab] OR "anabolic-androgenic"[tiab]); date 2026-10-02; human only count 3; animal filter count 1; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
How little research sits behind sleep
A PubMed search of CJC-1295 with sleep terms (2026-10-02) found 2 human-only papers and 0 under the animal filter; 0 carried a randomized-trial tag.
Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sleep*[tiab] OR insomni*[tiab]); date 2026-10-02; human only count 2; animal filter count 0; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)
More on CJC-1295
Common questions
Is CJC-1295 proven to work?
The strongest study we summarise for CJC-1295 is human rct evidence, among 7 studies. A trial result is not an approval; see the legal status.
What does CJC-1295 do?
In healthy adults CJC-1295 raised growth hormone and IGF-I concentrations in a dose-dependent way for days.[1]
What benefits do people claim for CJC-1295?
The benefits people name are weight loss, muscle, skin, sleep and healing, while the measured effect in trials is a rise in GH and IGF-I.[2]
Does CJC-1295 without DAC have benefits?
The cached review lists CJC-1295 with DAC and CJC-1295 without DAC as separate GHRH analogues, and the cached trial abstracts do not say which form was given.[5]
More on CJC-1295
Sources
- 1Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 2Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.Substance use & misuse · 2016PMID 26771670Accessed 2 Oct 2026
- 3Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009PMID 19386527Accessed 2 Oct 2026
- 4Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 5The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 6Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 7Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology · 2005PMID 15817669Accessed 2 Oct 2026
- 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.